HUMAN PLATELET LYSATE MARKET ANALYSIS
Global Human Platelet Lysate Market: Key Developments
In June 2021, Captivate Bio, a scientific cell culture solutions provider, announced that it has signed an exclusive distribution agreement with PL BioScience GmbH, a biotech company to bring its portfolio of human platelet lysate to markets across North America. PL BioScience GmbH produces human-derived platelet lysate (HPL), a growth factor-rich supplement used for growing and expanding cells for applications such as cell therapy and tissue engineering.
In May 2020, CiRA Foundation, an institute focused on cell research and CGT Catapult, a biotechnological center launched a new collaborative research project aimed on induced pluripotent stem cell characterization.
In June 2020, Japan's Pharmaceutical and Medical Devices Agency (PMDA) had approved the start of Phase 2 clinical trial to evaluate the safety and efficacy of their mesenchymal stem cells that can be used to treat aging frailty.
In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
